Drugs

, Volume 63, Issue 15, pp 1549–1563 | Cite as

Neurotoxic Complications of Chemotherapy in Patients with Cancer

Clinical Signs and Optimal Management
  • Carla C. P. Verstappen
  • Jan J. Heimans
  • Klaas Hoekman
  • Tjeerd J. Postma
Therapy In Practice

Abstract

Neurotoxic side effects of chemotherapy occur frequently and are often a reason to limit the dose of chemotherapy. Since bone marrow toxicity, as the major limiting factor in most chemotherapeutic regimens, can be overcome with growth factors or bone marrow transplantation, the use of higher doses of chemotherapy is possible, which increases the risk of neurotoxicity.

Chemotherapy may cause both peripheral neurotoxicity, consisting mainly of a peripheral neuropathy, and central neurotoxicity, ranging from minor cognitive deficits to encephalopathy with dementia or even coma.

In this article we describe the neurological adverse effects of the most commonly used chemotherapeutic agents.

The vinca-alkaloids, cisplatin and the taxanes are amongst the most important drugs inducing peripheral neurotoxicity. These drugs are widely used for various malignancies such as ovarian and breast cancer, and haematological cancers. Chemotherapy-induced neuropathy is clearly related to cumulative dose or dose-intensities. Patients who already have neuropathic symptoms due to diabetes mellitus, hereditary neuropathies or earlier treatment with neurotoxic chemotherapy are thought to be more vulnerable for the development of chemotherapy-induced peripheral neuropathy.

Methotrexate, cytarabine (cytosine arabinoside) and ifosfamide are primarily known for their central neurotoxic side effects. Central neurotoxicity ranges from acute toxicity such as aseptic meningitis, to delayed toxicities comprising cognitive deficits, hemiparesis, aphasia and progressive dementia. Risk factors are high doses, frequent administration and radiotherapy preceding methotrexate chemotherapy, which appears to be more neurotoxic than methotrexate as single modality.

Data on management and neuroprotective agents are discussed. Management mainly consists of cumulative dose-reduction or lower dose-intensities, especially in patients who are at higher risk to develop neurotoxic side effects. None of the neuroprotective agents described in this article can be recommended for standard use in daily practise at this moment, and further studies are needed to confirm some of the beneficial effects described.

Keywords

Paclitaxel Peripheral Nervous System Cytarabine Ifosfamide Amifostine 

Notes

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

References

  1. 1.
    Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999; 42: 73–7PubMedCrossRefGoogle Scholar
  2. 2.
    Boogerd W, Ten Bokkel Huinink WW, Dalesio O, et al. Cisplatin-induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990; 9: 255–63PubMedCrossRefGoogle Scholar
  3. 3.
    Lomonaco M, Milone M, Batocchli AP, et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 1992; 239: 199–204PubMedCrossRefGoogle Scholar
  4. 4.
    Siegal T, Haim N. Cisplatin-induced peripheral neuropathy: frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 15: 1117–23CrossRefGoogle Scholar
  5. 5.
    Riggs J, Ashraf M, Snyder RD, et al. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 1988; 23: 92–4PubMedCrossRefGoogle Scholar
  6. 6.
    Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795–803PubMedGoogle Scholar
  7. 7.
    Dewar J, Lunt H, Abernethy DA, et al. Cisplatin neuropathy with Lhermitte’s sign. J Neurol Neurosurg Psychiatry 1986; 49: 96–9PubMedCrossRefGoogle Scholar
  8. 8.
    van den Bent MJ, van Putten WL, Hilkens PH, et al. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neurotoxicity. Eur J Cancer 2002, 91Google Scholar
  9. 9.
    Gerritsen van der Hoop R, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89–94PubMedCrossRefGoogle Scholar
  10. 10.
    Neijt J, van der Burg M, Vecht C, et al. A double-blind randomized study with Org 2766, an ACTH(4–9) analog, to prevent cisplatin neuropathy [abstract A827]. Proc ASCO 1994; 13: 261Google Scholar
  11. 11.
    Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995; 13: 26–32PubMedGoogle Scholar
  12. 12.
    Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101–12PubMedGoogle Scholar
  13. 13.
    Rick O, Beyer J, Schwella N, et al. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 2001; 12: 1151–5PubMedCrossRefGoogle Scholar
  14. 14.
    Gradishar WJ, Stephenson P, Glover DJ, et al. A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188). Cancer 2001; 92: 2517–22PubMedCrossRefGoogle Scholar
  15. 15.
    Riccardi R, Riccardi A, Di Rocco C, et al. Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors. Cancer Chemother Pharmacol 1992; 30: 21–4PubMedCrossRefGoogle Scholar
  16. 16.
    O’Brien ME, Tonge K, Blake P, et al. Blindness associated with high-dose carboplatin [letter]. Lancet 1992; 339: 558PubMedCrossRefGoogle Scholar
  17. 17.
    Markman M, Kennedy A, Webster K, et al. Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 2001; 127: 55–8PubMedCrossRefGoogle Scholar
  18. 18.
    Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999; 26: 647–62PubMedGoogle Scholar
  19. 19.
    Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20: 1767–74PubMedCrossRefGoogle Scholar
  20. 20.
    Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406: 25–32PubMedCrossRefGoogle Scholar
  21. 21.
    Eckel F, Schmelz R, Adelsberger H, et al. Prevention of oxaliplatin-induced neuropathy by carbamazepine: a pilot study. Dtsch Med Wochenschr 2002; 127: 78–82PubMedCrossRefGoogle Scholar
  22. 22.
    Focan C, Olivier R, Le Hung S, et al. Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors. Cancer Chemother Pharmacol 1981; 6: 175–81PubMedCrossRefGoogle Scholar
  23. 23.
    Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336–41PubMedGoogle Scholar
  24. 24.
    Bain PG, Lantos PL, Djurovic V, et al. Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects. J Neurol 1991; 238: 230–4PubMedCrossRefGoogle Scholar
  25. 25.
    Hurwitz RL, Mahoney DH, Armstrong DL, et al. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988; 16: 216–9PubMedCrossRefGoogle Scholar
  26. 26.
    DeAngelis LM, Gnecco C, Taylor L, et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin’s lymphoma. Cancer 1991; 67: 2241–6PubMedCrossRefGoogle Scholar
  27. 27.
    Delaney P. Vincristine-induced laryngeal nerve paralysis. Neurology 1982; 32: 1285–8PubMedCrossRefGoogle Scholar
  28. 28.
    Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy: a clinical study of fifty leukemic patients. Neurology 1969; 19: 367–74PubMedCrossRefGoogle Scholar
  29. 29.
    Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut 1990; 61: 320–1PubMedCrossRefGoogle Scholar
  30. 30.
    Haim N, Epelbaum R, Ben-Sahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 15: 2515–9CrossRefGoogle Scholar
  31. 31.
    McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969; 32: 297–304PubMedCrossRefGoogle Scholar
  32. 32.
    Bradley WG, Lassman LP, Pearce GW, et al. The neuromyopathy of vincristine in man: clinical, electrophysiological and pathological studies. J Neurol Sci 1970; 10: 107–31PubMedCrossRefGoogle Scholar
  33. 33.
    Legha SS. Vincristine neurotoxicity, pathophysiology and management. Med Toxicol 1986; 1: 421–7PubMedGoogle Scholar
  34. 34.
    Postma TJ, Benard BA, Huijgens PC, et al. Long term effects of vincristine on the peripheral nervous system. J Neurooncol 1993; 15: 23–7PubMedCrossRefGoogle Scholar
  35. 35.
    Naumann R, Mohm J, Reuner U, et al. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol 2001; 115: 323–5PubMedCrossRefGoogle Scholar
  36. 36.
    van Kooten B, van Diemen HA, Groenhout KM, et al. A pilot study on the influence of a corticotropin (4–9) analogue on vinca-alkaloid-induced neuropathy. Arch Neurol 1992; 49: 1027–31PubMedCrossRefGoogle Scholar
  37. 37.
    Jackson DV, Wells HB, Atkins JN, et al. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988; 84: 1016–22PubMedCrossRefGoogle Scholar
  38. 38.
    Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high dose paclitaxel. Clin Cancer Res 1999; 5: 481–6Google Scholar
  39. 39.
    Seidman AD, Barrett S. Photopsia during 3-hour paclitaxel administration at doses > 250 mg/m2. J Clin Oncol 1994; 12: 1741–2PubMedGoogle Scholar
  40. 40.
    van Gerven JM, Moll JW, van den Bent MJ, et al. Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30: 1074–7CrossRefGoogle Scholar
  41. 41.
    Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489–94PubMedGoogle Scholar
  42. 42.
    Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241–8PubMedGoogle Scholar
  43. 43.
    Freilich RJ, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115–8PubMedCrossRefGoogle Scholar
  44. 44.
    Lorenz E, Hagen B, Himmelmann A, et al. A phase II study of biweekly administration of paclitaxel with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 1999; 9: 373–6PubMedCrossRefGoogle Scholar
  45. 45.
    Jerian SM, Sarosy GA, Link CJ, et al. Incapacitating autonomic neuropathy precipitated by Taxol. Gynecol Oncol 1993; 51: 277–80PubMedCrossRefGoogle Scholar
  46. 46.
    Sahenk Z, Barohn R, New P, et al. Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994; 51: 726–9PubMedCrossRefGoogle Scholar
  47. 47.
    Kaplan JG, Einzig AI, Schaumburg HH. Taxol causes permanent large fiber peripheral nerve dysfunction: a lesson for preventative strategies. J Neurooncol 1993; 16: 105–7PubMedCrossRefGoogle Scholar
  48. 48.
    Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405–10PubMedGoogle Scholar
  49. 49.
    Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368–73PubMedCrossRefGoogle Scholar
  50. 50.
    Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–66PubMedGoogle Scholar
  51. 51.
    Martoni A, Zamagni C, Gheka A, et al. Antihistamines in the treatment of taxol-induced paroxystic pain syndrome. J Natl Cancer Inst 1993; 85: 676PubMedCrossRefGoogle Scholar
  52. 52.
    Apfel SC, Lipton RB, Arezzo JC, et al. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87–90PubMedCrossRefGoogle Scholar
  53. 53.
    Hamers FP, Pette C, Neijt JP, et al. The ACTH(4–9) analog, Org2766 prevents Taxol-induced neuropathy in rats. Eur J Pharmacol 1993b; 233: 177–8CrossRefGoogle Scholar
  54. 54.
    Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 1999; 41: 107–16PubMedCrossRefGoogle Scholar
  55. 55.
    Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001; 7: 1192–7PubMedGoogle Scholar
  56. 56.
    Di Paola RS, Rodriguez R, Goodin S, et al. Amifostine and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther 1998; 1: 11–7Google Scholar
  57. 57.
    Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 3038–47PubMedGoogle Scholar
  58. 58.
    New PZ, Jackson CE, Rinaldi D, et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996; 46: 108–11PubMedCrossRefGoogle Scholar
  59. 59.
    Hilkens PH, Verweij J, Stoter G, et al. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104–8PubMedCrossRefGoogle Scholar
  60. 60.
    Vukelja SJ, Baker WJ, Burris III HA, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993; 85: 1432–3PubMedCrossRefGoogle Scholar
  61. 61.
    Mott MG, Stevenson P, Wood CB. Methotrexate meningitis. Lancet 1972; II: 656CrossRefGoogle Scholar
  62. 62.
    Bates S, McKeever P, Masur H, et al. Myelopathy following intrathecal chemotherapy in a patient with extensive Burkitt’s lymphoma and altered immune status. Am J Med 1985; 78: 697–702PubMedCrossRefGoogle Scholar
  63. 63.
    Genvresse I, Dietzmann A, Massenkeil G, et al. Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer. Anticancer Drugs 1999; 10: 293–4PubMedCrossRefGoogle Scholar
  64. 64.
    Kiu MC, Liaw CC, Yang TS, et al. Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anticancer Drugs 1994; 5: 480–2PubMedCrossRefGoogle Scholar
  65. 65.
    Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864–71PubMedGoogle Scholar
  66. 66.
    Lien HH, Blomlie V, Saeter G, et al. Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 1991; 179: 547–50PubMedGoogle Scholar
  67. 67.
    Moore BE, Somers NP, Smith TW. Methotrexate-related non-necrotizing multifocal axonopathy detected by betaamyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 2002; 126: 79–81PubMedGoogle Scholar
  68. 68.
    Koh S, Nelson Jr MD, Kovanlikaya A, et al. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999; 21: 576–8PubMedCrossRefGoogle Scholar
  69. 69.
    Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parental methotrexate: a prospective study. J Clin Oncol 1991; 9: 145–51PubMedGoogle Scholar
  70. 70.
    van den Berg H, van der Flier M, van de Wetering MD. Cytarabine-induced aseptic meningitis. Leukemia 2001; 15: 697–9PubMedCrossRefGoogle Scholar
  71. 71.
    Dunton SF, Nitschke R, Spruce WE, et al. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside: a Pediatric Oncology Group study. Cancer 1986; 57: 1083PubMedCrossRefGoogle Scholar
  72. 72.
    Kleinschmidt-DeMasters BK, Yeh M. “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer 1992; 70: 2504–7PubMedCrossRefGoogle Scholar
  73. 73.
    Resar LM, Phillips PC, Kastan MB, et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993; 71: 117–23PubMedCrossRefGoogle Scholar
  74. 74.
    Herzig RH, Hines JD, Herzig GP. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987; 5: 927–32PubMedGoogle Scholar
  75. 75.
    Gottlieb D, Bradstock K, Koutts J, et al. The neurotoxicity of high-dose cytosine arabinoside is age related. Cancer 1987; 60: 1439–41PubMedCrossRefGoogle Scholar
  76. 76.
    Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high-dose cytosine arabinoside. Cancer 1983; 51: 430–2PubMedCrossRefGoogle Scholar
  77. 77.
    Shaw PJ, Procopsis PG, Menser MA. Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia. Med Pediatr Oncol 1991; 19: 122–5PubMedCrossRefGoogle Scholar
  78. 78.
    Hoffman DL, Howard JR Jr, Sarma R, et al. Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol 1993; 16: 258–62PubMedCrossRefGoogle Scholar
  79. 79.
    Russell JA, Powles RL. Neuropathy due to cytosine arabinoside. BMJ 1974; 4: 652–3PubMedCrossRefGoogle Scholar
  80. 80.
    Powell BL, Capizzi RL, Lyerly ES, et al. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin and asparaginase consolidation for acute nonlymphocytic leukemia. J Clin Oncol 1986; 4: 95–7PubMedGoogle Scholar
  81. 81.
    Scherokman B, Filling-Katz MR, Tell D. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Cancer Treat Rep 1985; 69: 1005–6PubMedGoogle Scholar
  82. 82.
    Borgeat A, De Muralt B, Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 1986; 58: 852–4PubMedCrossRefGoogle Scholar
  83. 83.
    Courtney MJ, Coffey ET. The mechanism of ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci 1999; 11: 1073–84PubMedCrossRefGoogle Scholar
  84. 84.
    Takimoto CH, Lu ZH, Ahang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2: 477–81PubMedGoogle Scholar
  85. 85.
    Bixenman WW, Nicholls JV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977; 83: 789–93PubMedGoogle Scholar
  86. 86.
    Bergevin PR, Patwardhan VC, Weissman J, et al. Neurotoxicity of 5-fluorouracil [letter]. Lancet 1975; I: 410CrossRefGoogle Scholar
  87. 87.
    Howell SB, Pfeifle CE, Wung WE. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. Cancer 1983; 51: 220–5PubMedCrossRefGoogle Scholar
  88. 88.
    Israel ZH, Lossos A, Barak V, et al. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncol 2000; 39: 117–20PubMedCrossRefGoogle Scholar
  89. 89.
    Saif MW, Wilson RH, Harold N, et al. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 2001; 12: 525–31PubMedCrossRefGoogle Scholar
  90. 90.
    DiMaggio JR, Brown R, Baile WF, et al. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994; 73: 1509–14PubMedCrossRefGoogle Scholar
  91. 91.
    Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcoma. Results of phase II and pilot studies: dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378–84Google Scholar
  92. 92.
    Curtin JP, Koonings PP, Gutierrez M, et al. Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991; 42: 193–6PubMedCrossRefGoogle Scholar
  93. 93.
    Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986; 4: 1253–61PubMedGoogle Scholar
  94. 94.
    Pelgrims J, de Vos F, van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82: 291–4PubMedCrossRefGoogle Scholar
  95. 95.
    Kende G, Sirkin SR, Thomas PR, et al. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer 1979; 44: 69–71PubMedCrossRefGoogle Scholar
  96. 96.
    Tashima CK. Immediate cerebral symptoms during rapid intravenous administration of cyclophosphamide (NSC-26271). Cancer Chemother Rep 1975; 59: 441–2PubMedGoogle Scholar
  97. 97.
    Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982; 100: 1766–72PubMedCrossRefGoogle Scholar
  98. 98.
    Rosenblum MK, Delattre J-Y, Walker RW, et al. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol 1989; 7: 269–81PubMedCrossRefGoogle Scholar
  99. 99.
    Wilson WB, Perez GM, Kleinschmidt-DeMasters BK. Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. Cancer 1987; 59: 901–7PubMedCrossRefGoogle Scholar
  100. 100.
    Postma TJ, van Groeningen CJ, Witjes RJ, et al. Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 1998; 38: 69–75PubMedCrossRefGoogle Scholar
  101. 101.
    Spivack SD. Procarbazine. Ann Int Med 1974; 81: 795–800PubMedGoogle Scholar
  102. 102.
    Imrie KR, Couture F, Turner CC, et al. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 77–9PubMedGoogle Scholar
  103. 103.
    Leff RS, Thompson JM, Daly MB, et al. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer 1988; 62: 32–5PubMedCrossRefGoogle Scholar
  104. 104.
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210–8PubMedCrossRefGoogle Scholar
  105. 105.
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485–93PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Carla C. P. Verstappen
    • 1
  • Jan J. Heimans
    • 1
  • Klaas Hoekman
    • 2
  • Tjeerd J. Postma
    • 1
  1. 1.Department of NeurologyVrije Universiteit Medical CenterAmsterdamThe Netherlands
  2. 2.Medical OncologyVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations